AB 384: Information privacy: digital health feedback systems.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-06-25
|
Date
|
Status
|
|---|---|
| Aug 30, 2019 | In committee: Held under submission. |
| Aug 12, 2019 | In committee: Referred to APPR. suspense file. |
| Jul 10, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 6. Noes 1.) (July 9). Re-referred to Com. on APPR. |
| Jul 5, 2019 | From committee: Do pass and re-refer to Com. on JUD. (Ayes 7. Noes 1.) (July 3). Re-referred to Com. on JUD. |
| Jun 25, 2019 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 12, 2019 | Referred to Coms. on HEALTH and JUD. |
| May 30, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 29, 2019 | Read third time. Passed. Ordered to the Senate. |
| May 2, 2019 | Read second time. Ordered to third reading. |
| May 1, 2019 | From committee: Do pass. (Ayes 13. Noes 5.) (May 1). |
| Apr 24, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 2.) (April 23). Re-referred to Com. on APPR. |
| Mar 27, 2019 | From committee: Do pass and re-refer to Com. on P. & C.P. (Ayes 10. Noes 3.) (March 26). Re-referred to Com. on P. & C.P. |
| Mar 19, 2019 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Feb 15, 2019 | Referred to Coms. on HEALTH and P. & C.P. |
| Feb 6, 2019 | From printer. May be heard in committee March 8. |
| Feb 5, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 12, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 9, 2019 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Judiciary |
Passed |
|
| Jul 3, 2019 | Do pass, but first be re-referred to the Committee on [Judiciary] | Senate Standing Committee on Health |
Passed |
|
| May 29, 2019 | AB 384 Chau Assembly Third Reading | Assembly Floor |
Passed |
|
| May 1, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 23, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Privacy and Consumer Protection |
Passed |
|
| Mar 26, 2019 | Do pass and be re-referred to the Committee on [Privacy and Consumer Protection] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 384 (Chau) - Information privacy: digital health feedback systems
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
Assembly Bill 384 would make a business a provider of health care, and subject “personal health record information,” as defined, to the Confidentiality of Medical Information Act (CMIA).
Fiscal Impact:
- $214,000 General Fund in FY 2019-20 and $364,000 in FY 2020-21, and ongoing, for the Department of Justice (DOJ) to hire and train 1.0 Deputy Attorney General and 1.0 legal secretary to pursue enforcement actions and increased workload. The DOJ anticipates 3 additional cases yearly, which takes approximately 285 hours of review each, which totals 854 hours of additional DAG workload on an annual basis. These hours convert to a little over 0.5 of a position, which was rounded up to a whole position in standard costing.
- Unknown, potentially-significant workload cost pressures to the court to adjudicate any civil actions, civil fines, and misdemeanor charges filed against defendants who violate the provisions added to CMIA by this measure. While the superior courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources. For example, the 2018 Budget Act appropriated $64 million from the General Fund to backfill continued reduction in fine and penalty revenue for trial court operations. (General Fund*)
- Unknown potential increase in non-reimbursable local enforcement and incarceration costs to prosecute and incarcerate those charged with and found guilty of conduct proscribed by this bill. Costs would be offset, to a degree, by fee and assessment revenue. (Local funds)
*Trial Court Trust Fund
Background:
California’s Confidentiality of Medical Information Act (CMIA) allows adult patients in California to keep personal health information confidential and decide whether and when to share that information. These provisions are guided to protect Californians’ right to privacy. The CMIA provides a definition for what constitutes “medical information,” and therefore what is protected under the CMIA.”
The federal Health Information Portability and Accountability Act (HIPAA) established patient privacy protections for a patient’s “protected health information,” and prohibits a covered entity (e.g., health plan, health care provider, or health care clearing house) from using or disclosing specified protected health information (45 CFR §164.500, et seq.). The HIPAA institutes consumer privacy protections related to specified health information and requires reasonable efforts to limit disclosure of that information to the minimum amount necessary to accomplish the intended purpose when using, disclosing, or requesting protected health information.
A violation of CMIA is actionable in a few different ways. Existing law provides a private right of action to a person whose confidential information or records were negligently released by a person or entity subject to CMIA. The person may recover either or both nominal damages of $1,000 and/or actual damages. Additionally, a violation of CMIA that results in economic loss or personal injury to a patient is a misdemeanor, punishable by incarceration of up to six months in county jail and/or a base fine of up to $1,000. Lastly, the CMIA imposes liability in the form of administrative fines and civil penalties for specified violations. A person or entity that negligently discloses medical information in violation of CMIA is liable for an administrative fine or civil penalty of up to $2,500 per violation. A person or entity, other than a licensed health care professional, that knowingly and willfully obtains, discloses, or uses medical information in violation of CMIA is liable for an administrative fine or civil penalty of up to $25,000 per violation.
According to the author, recent technology, such as “digital pills” that can send information from the digestive tract or bloodstream to a patient or patient’s caregivers’ mobile phones, tablets, and computer, raise privacy and data security concerns.
Proposed Law:
AB 384 includes the following provisions, among others:
- Deems any business that offers personal health record software or hardware to a consumer, including a mobile application or other related device that is designed to maintain personal health record information for purposes of information management, or for the diagnosis, treatment, or management of a medical condition, to be deemed to be a provider of health care, subject to the CMIA.
- Defines several key terms including:
- “Personal health record” as an FDA-approved commercial internet website, online service, or product that is used by an individual at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information.
- “Personal health record information” means individually identifiable information, in electronic or physical form, about an individual’s mental or physical condition that is collected by a personal health record through a direct measurement of an individual’s mental or physical condition or through user input regarding an individual’s mental or physical condition into a personal health record.
Related Legislation:
- AB 2167 (Chau, 2018) would have amended the Confidentiality of Medical Information Act (CMIA) by expanding the definition of “medical information.” The bill failed passage on the Senate Floor.
- SB 327 (Jackson, Chapter 886, Statutes of 2018) would have required a manufacturer that sells or offers to sell a connected device to equip the device with reasonable security features appropriate to the nature of the device.
Staff Comments:
The fiscal impact of this bill cannot be known with certainty, as the actual impact will be dependent on numerous factors, including, but not limited to, the frequency with which persons and entities are accused of violating CMIA, the complexity of alleged violations, if parties settle matters prior to litigation, and the factors unique to each case. It costs the court a little over $2,600, on average, in personnel and resources to adjudicate a limited civil case and a little over $11,600, on average, in personnel and resources to adjudicate an unlimited civil case. Also, it generally costs about $7,010 to operate a courtroom for one day. So if violations of the expansion of CMIA proposed by this bill led to more than nineteen new limited civil cases, more than four unlimited civil cases, a dozen or more misdemeanor charges, or a few complex case that took longer than seven days, the cost pressures of this bill to the court would surpass the Suspense File threshold.
-- END --
Senator Hannah-Beth Jackson, Chair
2019-2020 Regular Session
Bill No: AB 384 (Author:Chau)
Version: June 25, 2019
Hearing Date: July 9, 2019
Fiscal: Yes
Urgency: No
Consultant: CK
SUBJECT
Information privacy: digital health feedback systems
DIGEST
This bill makes a business a provider of health care, and therefore subject to California’s Confidentiality of Medical Information Act (CMIA), when it offers personal health record software or hardware that is designed to maintain and make available personal health record information for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition of the individual.
EXECUTIVE SUMMARY
Existing California and federal law contain a number of provisions relating to the use of a patient’s medical information. These statutory frameworks favor the privacy of the patient, with caveats to the sharing of patient’s medical information when necessary for treatment. California’s CMIA allows adult patients in California to keep personal health information confidential and decide whether and when to share that information. CMIA provides a definition for what constitutes “medical information,” and therefore what is protected under CMIA.
The use of certain digital health products and services that collect, transmit certain health data raises some serious privacy concerns. This bill defines “personal health record” (PHR) as a federal Food and Drug Administration (FDA) approved commercial internet website, online service, or product that is used by an individual at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information. It deems a business that offers PHR software or hardware a “provider of health care” and subjects it to the provisions of CMIA.
The bill is sponsored by the author and supported by Consumer Reports. It is opposed by Advanced Medical Technology Association and California Life Sciences Association. This bill passed out of the Senate Health Committee on a 7-1 vote.
PROPOSED CHANGES TO THE LAW
Existing federal law:
- Establishes the Health Insurance Portability and Accountability Act (HIPAA), which provides privacy protections for patients’ protected health information and generally prohibits a covered entity, as defined (health plan, health care provider, and health care clearing house), from using or disclosing protected health information except as specified or as authorized by the patient in writing. (45 C.F.R. § 164.500 et seq.)
- Provides that if HIPAA’s provisions conflict with a provision of state law, the provision that is the most protective of patient privacy prevails. (45 C.F.R. § 164.500 et seq.)
Existing state law:
- Provides, pursuant to the California Constitution, that all people are by nature free and independent and have inalienable rights. Among these are enjoying and defending life and liberty, acquiring, possessing, and protecting property, and pursuing and obtaining safety, happiness, and privacy. (Cal. Const., art. I, § 1.)
- Establishes the CMIA, which establishes protections for the use of medical information. (Civ. Code § 56 et seq.)
- Prohibits providers of health care, health care service plans, or contractors, as defined, from sharing medical information without the patient’s written authorization, subject to certain exceptions. (Civ. Code § 56.10.)
- Provides that every provider of health care, health care service plan, pharmaceutical company, or contractor who creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information shall do so in a manner that preserves the confidentiality of the information contained therein. Any provider of health care, health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information shall be subject to remedies and penalties, as specified. (Civ. Code § 56.101.)
- Defines “patient,” for purposes of CMIA, to mean any natural person, whether or not still living, who received health care services from a provider of health care and to whom medical information pertains. (Civ. Code § 56.05(k).)
- Defines “medical information,” for purposes of CMIA, to mean any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment. “Individually identifiable” means that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, or social security number, or other information that, alone or in combination with other publicly available information, reveals the individual’s identity. (Civ. Code § 56.05(j).)
- Defines “health care service plan” to mean any entity regulated pursuant to the Knox-Keene Health Care Service Plan Act of 1975. (Civ. Code § 56.05(g).)
- Defines a “licensed health care professional,” for purposes of CMIA, to mean any person licensed or certified pursuant to the Business and Professions Code, the Osteopathic Initiative Act or the Chiropractic Initiative Act, or the Health and Safety Code, as specified. (Civ. Code § 56.05(h).)
- Defines “provider of health care,” for purposes of CMIA, to mean any person licensed or certified pursuant to the Business and Professions Code, as specified; the Osteopathic Initiative Act or the Chiropractic Initiative Act; the Health and Safety Code, as specified; or any licensed clinic, health dispensary, or health facility, as specified. The term does not include insurance institutions, as defined. (Civ. Code § 56.05(m).)
- Provides that any business organized for the purpose of maintaining medical information in order to make the information available to an individual or to a provider of health care at the request of the individual or the provider of health care, for purposes of allowing the individual to manage his or her information, or for the diagnosis and treatment of the individual, shall be deemed to be a provider of health care subject to the requirements of CMIA. (Civ. Code § 56.06(a).)
- Provides that any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information in order to make the information available to an individual or a provider of health care at the request of the individual or a provider of health care, for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition of the individual, shall be deemed to be a provider of health care subject to the requirements of CMIA. (Civ. Code § 56.06(b).)
- Provides that any business described in the preceding two paragraphs must maintain the same standards of confidentiality required of a provider of health care with respect to medical information disclosed to the business. Such businesses are subject to the penalties for improper use and disclosure of medical information prescribed in CMIA. (Civ. Code § 56.06(c), (d).)
- Provides that any provider of health care, a health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of written or electronic medical records shall be subject to damages in a civil action or an administrative fine, as specified. (Civ. Code § 56.36.)
- Establishes the California Consumer Privacy Act (CCPA). The CCCPA does not apply to medical information governed by CMIA. (Civ. Code § 1798.145.)
This bill:
- Defines “personal health record” as an FDA-approved commercial internet website, online service, or product that is used by an individual at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information.
- Defines “personal health record information” to mean individually identifiable information, in electronic or physical form, about an individual’s mental or physical condition that is collected by a personal health record through a direct measurement of an individual’s mental or physical condition or through user input regarding an individual’s mental or physical condition into a personal health record.
- Provides that any business that offers personal health record software or hardware to a consumer, including a mobile application or other related device that is designed to maintain personal health record information, as defined in subdivision (m) of Section 56.05, in order to make information available to an individual or to a provider of health care at the request of the individual or provider of health care, for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition of the individual, shall be deemed to be a provider of health care subject to the requirements of this part.
COMMENTS
- Protections for medical information
HIPAA, enacted in 1996, guarantees privacy protection for individuals with regards to specific health information. (Pub.L. 104–191, 110 Stat. 1936.) Generally, protected health information is any information held by a covered entity which concerns health status, provision of healthcare, or payment for healthcare that can be connected to an individual. HIPAA privacy regulations require healthcare providers and organizations to develop and follow procedures that ensure the confidentiality and security of personal health information when it is transferred, received, handled, or shared. HIPAA further requires reasonable efforts when using, disclosing, or requesting protected health information, to limit disclosure of that information to the minimum amount necessary to accomplish the intended purpose.
CMIA (Civ. Code § 56 et seq.) allows adult patients in California to keep personal health information confidential and decide whether and when to share that information. These provisions are guided to protect Californians’ fundamental right to privacy. (Cal. Const., art. I, § 1.) CMIA provides a definition for what constitutes “medical information,” and therefore what is protected under CMIA.
- Extending existing protections to sensitive medical information
In November 2017, the FDA approved its first digital drug. The drug came in the form of a pill with an embedded sensor that has the capability to determine and transmit whether someone has taken it. The sensor inside this pill is the size of a grain of sand and detects and records when it is ingested, sending that information to a patch worn by the patient. The patch thereafter transmits the information to an application that can be downloaded to a smartphone.
As with many technological advances and innovations, this breakthrough comes with serious concerns about privacy. These pills are just one example of emerging technology that assists medical professionals and consumers address health care concerns; others include fitness applications, advanced medical software, and other digital health products. This bill provides protections for the information collected by these various products and services by making businesses that offer them providers of health care and subjecting them to the mandates of CMIA.
This bill defines PHR as an FDA-approved commercial internet website, online service, or product that is used by an individual at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information. PHR information is the individually identifiable information, in electronic or physical form, about an individual’s mental or physical condition that is collected by a PHR through a direct measurement of an individual’s mental or physical condition or through user input regarding an individual’s mental or physical condition into a personal health record.
In order to bring PHR and PHR information with the scope of protections of CMIA, this bill makes certain businesses offering PHR software or hardware, “providers of health care” and subjects them to CMIA. The type of offerings would include a mobile application or other device that is intended to maintain PHR information with the intent to make it available to an individual or a health care provider, at their request, for the purpose of managing the data or using it for diagnosis, treatment, or management of medical conditions.
Providers of health care are subject to various requirements under CMIA. They are prohibited from sharing medical information without the patient’s written authorization, subject to certain exceptions. (Civ. Code § 56.10.) A provider of health care who creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information is required to do so in a manner that preserves the confidentiality of the information contained therein. Any provider of health care who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information is subject to certain penalties. (Civ. Code § 56.101.) If a provider negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of written or electronic medical records, they are subject to damages in a civil action or an administrative fine, as specified. (Civ. Code § 56.36.)
Pulling the businesses that offer the software and hardware that tap into this sensitive information into the ambit of CMIA is arguably a good first step in protecting consumers’ and patients’ medical privacy.
- Support and Opposition
According to the author:
While technology stands to improve how healthcare is delivered, these advancements do not come without risk. Health and medical information is, by its very nature, deeply personal and sensitive. New technology makes medical information easily and quickly accessible via apps and websites, and California has ensured that medical information held by mobile devices is protected under our privacy laws. However, in order to be considered “medical information,” this information generally needs to be generated by a health care provider. Information generated by digital health applications, which is often at the patient level and outside of a medical facility, is not necessarily captured under the existing definition of medical information. However, information about whether a patient took their medication and how that medication interacted in their body is unquestionably of a medical nature, as is information about the treatment of substance abuse disorders, and the like. Therefore, it is imperative that the information generated by digital health applications is classified as medical information, and the developers and operators of related hardware, software, and applications are prohibited from sharing this information and data without the patient’s informed consent.
Writing in opposition, AdvaMed and California Life Sciences Association argue the “additional liability under the California Medical Information Act (CMIA) is unnecessary and overly burdensome.” They assert that “thoroughly comprehensive regulatory and policy frameworks exist at both the national and international levels,” undermining the need for this legislation.
SUPPORT
Consumer Reports
OPPOSITION
Advanced Medical Technology Association
California Life Sciences Association
RELATED LEGISLATION
Pending Legislation: None known
Prior Legislation:
SB 327 (Jackson, Ch. 886, Stats. 2018) requires manufacturers of connected devices to equip those devices with reasonable security features appropriate to the nature of the device.
AB 2167 (Chau, 2018) would have amended CMIA to include within the definition of “medical information” any information in possession of, or derived from, a digital health feedback system. This bill failed passage on the Senate Floor.
AB 658 (Calderon, Ch. 296, Stats. 2013) applies the prohibitions of CMIA to any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information to allow an individual to manage the individual’s information, or for the diagnosis, treatment, or management of a medical condition of the individual.
AB 1298 (Jones, Ch. 699, Stats. 2007) subjected any business organized to maintain medical information for purposes of making that information available to an individual or to a health care provider, as specified, to the provisions of CMIA.
PRIOR VOTES:
Senate Health Committee (Ayes 7, Noes 1)
Assembly Floor (Ayes 57, Noes 15)
Assembly Appropriations Committee (Ayes 13, Noes 5)
Assembly Privacy and Consumer Protection Committee (Ayes 9, Noes 2)
Assembly Health Committee (Ayes 10, Noes 3)
**************
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: AB 384
AUTHOR: | Chau | ||
VERSION: | June 25, 2019 | ||
HEARING DATE: | July 3, 2019 | ||
CONSULTANT: | Vincent D. Marchand | ||
SUBJECT: Information privacy: digital health feedback systems
SUMMARY:
Subjects individually identifiable health information, collected by an FDA-approved internet website, online service, or product that is used by an individual at the direction of a health care provider, to the protections of the Confidentiality of Medical Information Act.
Existing law:
- Establishes the Confidentiality of Medical Information Act (CMIA) in the Civil Code, which prohibits a health care provider, health care service plan, or contractor from disclosing medical information regarding a patient without first obtaining authorization. [CIV §56, et. seq.]
- Defines “medical information,” for purposes of the CMIA, as any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment. [CIV §56.05]
- Requires any business organized for the purposes of maintaining medical information in order to make the information available to an individual or to a provider of health care at the request of the individual or the provider of health care, for the purposes of allowing the individual to manage his or her information, or for the diagnosis or treatment of the individual, to be deemed a provider of health care subject to the CMIA. [CIV §56.06(a)]
- Requires any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information in order to make the information available to an individual or a provider of health care at the request of the individual or a provider of health care, for purposes of allowing the individual to manage his or her information, or for the diagnosis, treatment, or management of a medical condition of the individual, to be deemed a provider of health care subject to the CMIA. [CIV 56.06(b)]
- Requires, as part of the CMIA, that any provider of health care, health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of written or electronic medical records, to be subject to damages in a civil action or an administrative fine, as specified. [CIV §56.36]
Existing federal law: Establishes the Health Information Portability and Accountability Act of 1996 (HIPAA), which provides privacy protections for a patient’s “protected health information,” and prohibits a “covered entity,” defined as a health plan, health care provider, or health care clearing house, from using or disclosing protected health information except as specified or as authorized by the patient in writing. [45 CFR §164.500, et seq.]
This bill:
- Defines “personal health record,” for purposes of the CMIA, as an FDA-approved commercial website, online service, or product that is used by an individual at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information.
- Defines “personal health record information,” for purposes of the CMIA, as individually identifiable information, in electronic or physical form, about an individual’s mental or physical condition that is collected by a personal health record through a direct measurement of an individual’s mental or physical condition or through user input regarding an individual’s mental or physical condition into a personal health record.
- Deems the following to be a provider of health care subject to the CMIA: any business that offers personal health record software or hardware to a consumer, including a mobile application or other related device that is designed to maintain personal health record information, as defined by this bill, in order to make information available to an individual or to a provider of health care at the request of the individual or provider, for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition of the individual.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, this bill would have unknown, likely minor General Fund costs to the Department of Justice for information technology changes necessary to reflect the creation of a new crime.
PRIOR VOTES:
Assembly Floor: | 57 - 15 |
Assembly Appropriations Committee: | 13 - 5 |
Assembly Health Committee: | 10 - 3 |
COMMENTS:
- Author’s statement. According to the author, while technology stands to improve how healthcare is delivered, these advancements do not come without risk. Health and medical information is, by its very nature, deeply personal and sensitive. New technology makes medical information easily and quickly accessible via apps and websites, and California has ensured that medical information held by mobile devices is protected under our privacy laws. However, in order to be considered “medical information,” this information generally needs to be generated by a healthcare provider. Information generated by a digital health feedback system, meaning at the patient level and outside of a medical facility, is not necessarily captured under the existing definition of medical information. However, information about whether a patient took their medication and how that medication interacted in their body is unquestionably of a medical nature. Therefore, it is imperative that the information generated by digital health feedback systems is classified as medical information, and developers and operators of hardware, software, and applications are prohibited from sharing this information and data without the patient’s informed consent.
- Current medical privacy laws protect medical information created by a provider or health plan. In general, patient protections of medical information fall under two main bodies of law: HIPPA in federal law and the CMIA in California. HIPAA provides federal protections for patient’s health information held by “covered entities” and any “business associates” that a covered entity engages to help it carry out its health care activities. A covered entity can be a provider, a health plan, or a health care clearinghouse that processes health information it receives from another entity. While HIPAA establishes a federal floor for minimum privacy protections and the right of patients to access their health information, states are permitted to enact laws that provide greater privacy protections or rights. Under the CMIA, a health care provider, health care service plan, or contractor cannot disclose medical information regarding a patient without getting the patient’s written authorization. However, the definition of “medical information” in the CMIA is any individually identifiable medical information “in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor.” The author argues that because technology used by a consumer at home, such as a digital pill, is not “in possession of or derived from a provider of health care,” the information that is collected using this technology is not protected under the CMIA. This gap in the regulatory structure is what this bill is addressing, by extending the CMIA to health data that is collected by an FDA-approved product and used at the direction of a healthcare provider outside of the confines of the doctor’s office.
- Background on technology that this bill is seeking to regulate. According to information provided by the author, recent changes made by the FDA have made it easier for digital health products to be cleared and approved, and healthcare providers are able to get more accurate and useful information about their patients through the use of digital health. For example, several forms of “digital pills” that send information from places like the digestive tract or bloodstream are being developed, with a few already in use. These digital pills, which combine ingestible microchip sensors with pharmaceuticals, can operate in a number of ways. They can record whether, when, where and in what quantity a drug is released, as well as information about the physical state of the person taking the drug, such as temperature, activity level, heart rate, and respiration. Digital pills then transmit signals and information about the patient to devices like mobile phones, tablets, and computers belonging to the patient, the patient’s caregivers, or the patient’s doctor. The author points to a specific example of a digital drug approved by the FDA in 2017 which combined an antipsychotic drug with a sensor that signals smartphones once it reaches the gut so doctors can track whether patients are taking their medication.
These pills and their accompanying technology stand to provide information that may drastically improve the lives of many people. For example, an estimated 50% of patients with chronic diseases in developed countries do not take their medication, as prescribed. This can cause relapse and recurrence of chronic disease and results in an estimated $100 billion - $300 billion in avoidable healthcare costs. By measuring medication adherence, digital health feedback systems could allow healthcare professionals to more effectively tailor treatment of chronic diseases to individual patients, which could both lead to better health outcomes and save billions of dollars in healthcare costs. The FDA has also recently approved the ProAir Digihaler, a digital and mobile connected inhaler that comes with built-in sensors. Those sensors can detect whenever the device is used and even measure the strength of the user's inhalation. More importantly, the inhaler can send data on people's usage to its mobile app companion. By providing them with visual information, users can spot trends and ensure they're getting the right amount of medication, as well as share the information with their doctors.
The author states that these examples represent only a handful of the recently FDA approved apps and devices in the digital health arena, and the medical advances these technologies may help deliver are promising. Yet, despite digital health’s potential for positive impact, there are significant concerns related to privacy and data security, which may act as barriers to their success. Specifically, how should information created and collected by these systems be disclosed, and to whom? Which privacy laws should apply to ensure that data created and transmitted via digital health applications is secure? The author quotes Ameet Sarpatwari, an instructor in medicine at Harvard Medical School, who told The New York Times that the digital pill “has the potential to improve public health. [But] if used improperly, it could foster more mistrust instead of trust.” - FDA regulation of digital devices and mobile apps. This bill applies the protections of the CMIA to personal health information that is collected by a “personal health record,” by defining any business that offers personal health record software or hardware to a consumer for certain purposes as a provider of health care. This bill defines a “personal health record,” in part, as an “FDA-approved commercial internet website, online service, or product” used by an individual with the primary purpose of collecting individually identifiable health information.
The FDA’s Center for Devices and Radiological Health has established the Digital Health Program to develop and implement regulatory strategies and policies for digital health technologies. According to the FDA, it has been working to provide clarity using practical approaches that balance benefits and risks of wireless medical devices, mobile medical apps, medical device data systems, medical device interoperability, software as a medical device, and other technology. In a guidance document, the FDA states that it is taking a tailored, risk-based approach to the regulation of mobile medical apps, focusing on the small subset of mobile apps that are intended to be used as an accessory to a regulated medical device, or transform a mobile platform into a regulated medical device. - Double referral. This bill is double referred. Should it pass out of this committee, it will be referred to the Senate Judiciary Committee.
- Prior legislation. AB 2167 (Chau of 2018) would have amended the CMIA to include within the definition of “medical information” any information in possession of, or derived from, a digital health feedback system. AB 2167 would have required manufacturers or operators that sell devices or applications that may be used as part of these digital health feedback systems to equip them with reasonable security features, as specified. AB 2167 failed passage on the Senate Floor.
AB 375 (Chau, Chapter 55, Statutes of 2018) provides consumers the right to access their personal information that is collected by a business, the right to delete it, the right to know what personal information is collected, the right to know whether and what personal information is being sold or disclosed, the right to stop a business from selling their information, and the right to equal service and price. Each right contains certain exceptions. Provides a modified, private right of action for data breaches and allows for enforcement by the Attorney General for other violations with a right to cure for businesses in violation, as specified.
AB 2747 (Assembly Committee on Judiciary, Chapter 913, Statutes of 2014) extends CMIA provisions to any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information in order to make the information available to an individual or a provider of health care at the request of the individual or a provider of health care.
AB 658 (Calderon, Chapter 296, Statutes of 2013) applies the prohibitions of CMIA to any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information to allow an individual to manage his or her information, or for the diagnosis, treatment, or management of a medical condition of the individual.
AB 1298 (Jones, Chapter 699, Statutes of 2007) subjected any business organized to maintain medical information for purposes of making that information available to an individual or to a health care provider, as specified, to the provisions of the CMIA. - Support if amended. Consumer Reports states that it has supported earlier versions of this bill because it would extend existing health privacy protections to innovative medical technology not contemplated when current laws were put in place. Consumer Reports states that current laws only protect sensitive health information that is generated by healthcare providers, insurers and health plans, pharmaceutical companies, healthcare clearinghouses and businesses organized for the purpose of maintaining medical information. According to Consumer Reports, the information created by new health technology, such as digital health feedback systems and online health services, do not fall into this rubric. However, Consumer Reports states that the provisions of this bill that limit its application to health technology that is both FDA-approved and used at the direction of a healthcare provider is overly restrictive and risks significant confusion. According to Consumer Reports, restricting this bill to only the health technology that is FDA-approved could create a disincentive to go through the FDA-approval process and could create an uneven framework between products that are similar but-for-FDA-approval. Additionally, Consumer Reports states that limiting the bill to covering only health technology that is used “at the direction of a provider of health care with the primary purpose of collecting the individual’s individually identifiable personal health record information” could create confusion and a loophole.
- Opposition to prior version. The Advanced Medical Technology Association (AdvaMed) and the California Life Sciences Association (CLSA) submitted a joint letter of opposition to the prior version of this bill. They are still reviewing the current version of the bill. According to their opposition letter to the prior version of the bill, AdvaMed and CLSA state that it is important to note that use of this technology requires willing and knowing participation from the patient, and that the patient maintains ownership and control of any data that is generated. As manufacturers already grant total control and ownership to the patient, if data were used in any other way, the manufacturer would be in violation of the prohibition against unfair and deceptive business practices, enforced by the Federal Trade Commission. AdvaMed and CLSA state that they remain unclear as to exactly what existing problem or what identified defect in the technology or in existing law this legislation aims to cure.
SUPPORT AND OPPOSITION:
Support: None received
Oppose: Advanced Medical Technology Association (prior version)
California Life Sciences Association (prior version)
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 384
Author:(Chau)
As Introduced Ver:February 5, 2019
Majority vote
SUMMARY:
Revises the Confidentiality of Medical Information Act (CMIA), to expand the definition of medical information to include any individually identifiable information in electronic or physical form in possession of, or derived from, a digital health feedback system, as defined. Requires a manufacturer that sells or offers to sell a device or software application that may be used with a digital health feedback system to a consumer in California to equip the device or software application, and system with reasonable security features appropriate to the nature of the device, system application, and system, and the information it may collect, contain, or transmit; and, to protect the system and any information from unauthorized access, destruction, use, modification, or disclosure.
Major Provisions
COMMENTS:
A 2017 New York Times article described that for the first time, the United States Food and Drug Administration has approved a digital pill, specifically, a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine. This approval marks a significant advance in the growing field of digital devices designed to monitor medicine-taking and to address the issue of patients not taking drugs as prescribed. The article notes that experts estimate that so-called nonadherence or noncompliance to medication costs about $100 billion a year because patients get sicker and need additional treatment or hospitalization. Patients who agree to take the digital medication can sign consent forms allowing their doctors and up to four other people, including family members, to receive electronic data showing the date and time pills are ingested. A smartphone app will allow patients to block recipients anytime they change their mind. Although voluntary, the technology is still likely to prompt questions about privacy and whether patients might feel pressured to take medication in a form their doctors can monitor. The article also notes that companies are developing digital medication technologies, including another ingestible sensor and visual recognition technology capable of confirming whether a patient has placed a pill on the tongue and has swallowed it and not all will need regulatory clearance, and some are already being used or tested in patients with heart problems, stroke, HIV, diabetes and other conditions.
A 2016 Vanderbilt Journal of Entertainment and Technology Law article, titled "Just What the Doctor Ordered: Protecting Privacy Without Impeding Development of Digital Pills," analyzed digital pills in the context of the privacy and data security implications that could put consumers at risk. Digital pills that send information from places like the human digestive tract or bloodstream are being developed, with a few already in use. These pills could stand to provide information that could drastically improve the lives of many people, but they also have privacy and data security implications that could put consumers at great risk. The article notes that ingestible sensors have great potential to provide financial and health related benefits. The risks of the digital pill with regard to privacy and data security, however, may lead some to call for preemptive regulation. The article contends that rather than immediately limiting information use, policymakers should focus on improving the methods by which consumers can be educated and give consent. The article also states that it is not clear which privacy laws will actually apply to digital pills as HIPAA applies only to individually identifiable health information that is stored or transmitted by "covered entities" and their "business associates." Covered entities are usually health care providers, health insurers, or health care clearinghouses that process billing information, not pharmaceutical companies. Pharmaceutical companies can be considered "business associates" if they perform "functions or activities on behalf of, or certain services for, a covered entity that involve the use or disclosure of protected health information.
According to the Author:
While technology stands to improve how healthcare is delivered, these advancements do not come without risk. Health and medical information is, by its very nature, deeply personal and sensitive. New technology makes medical information easily and quickly accessible via smartphone applications (apps) and Websites, and California has ensured that medical information held by mobile devices is protected under our privacy laws. However, in order to be considered "medical information," this information generally needs to be generated by a healthcare provider. Information that is generated by a digital health feedback system, meaning at the patient level and outside of a medical facility, will not necessarily be captured under the existing definition of medical information. But information about whether a patient took his or her medication and how that medication interacted in his or her body is unquestionably of a medical nature, according to the author. Therefore, it is imperative that the information generated by digital health feedback systems is classified as medical information, and developers and operators of hardware, software, and applications are prohibited from sharing this information and data without the patient's informed consent.
Arguments in Support:
Consumer Reports (CR) state that this bill's protections would add certainty for patients that using smart pills will not jeopardize their privacy and potentially impact them in other areas of their lives. CR state that it is critical that this bill be put in place as the marketplace for this type of medical technology expands and becomes a prevalent feature of healthcare.
Arguments in Opposition:
Advanced Medical Technology Association and the California Life Sciences Association (AdvaMed and CLSA) are opposed to this bill because it would impose a new and undefined "reasonable security features" standard on a constantly evolving and innovating field, creating persistent questions of liability for the industry and/or a constant game of catch-up by California regulators. AdvaMed and CLSA also contend that thoroughly comprehensive regulatory and policy frameworks exist at both the national and international levels which are continuing to evolve.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, this bill would have unknown, likely minor General Fund costs to the Department of Justice for information technology changes necessary to reflect the creation of a new crime.
VOTES:
ASM HEALTH: 10-3-2
YES: Wood, Aguiar-Curry, Bonta, Carrillo, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago
NO: Bigelow, Flora, Waldron
ABS, ABST OR NV: Mayes, Burke
ASM PRIVACY AND CONSUMER PROTECTION: 9-2-0
YES: Chau, Bauer-Kahan, Berman, Calderon, Gabriel, Gallagher, Irwin, Smith, Wicks
NO: Kiley, Obernolte
ASM APPROPRIATIONS: 13-5-0
YES: Gonzalez, Bloom, Bonta, Calderon, Carrillo, Chau, Friedman, Gabriel, Eduardo Garcia, Maienschein, Petrie-Norris, Jones-Sawyer, Robert Rivas
NO: Bigelow, Brough, Diep, Fong, Obernolte
UPDATED:
VERSION: February 5, 2019
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0000339
Date of Hearing: May 1, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 384
Author:(Chau) – As Introduced Ver:February 5, 2019
Policy Committee: | Health | Vote: | 10 - 3 |
Privacy and Consumer Protection | 9 - 2 | ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill establishes privacy protections for digital health feedback systems. Specifically, this bill:
- Defines "digital health feedback system" as an ingestible sensor that collects or sends information about an individual and is used in conjunction with another device or software platform.
- Protects the privacy of information in possession of or derived from a digital health feedback system by including such information in the definition of medical information.
- Requires a manufacturer or operator that sells or offers to sell a device or software application that may be used with a digital health feedback system to a consumer in California to equip the device or software application, and the system, with reasonable security features and to protect information from unauthorized disclosure.
FISCAL EFFECT:
Unknown, likely minor GF costs to the Department of Justice for information technology changes necessary to reflect the creation of a new crime.
COMMENTS:
- Purpose. This author-sponsored bill seeks to implement reasonable regulations for the use of “digital pills.” First, it would define “digital health feedback system.” Second, by amending the definition of “medical information” in the Confidentiality of Medical Information Act (CMIA), this bill would ensure information derived from or in the possession of these systems is subject to California’s medical privacy laws. Finally, this bill would require manufacturers equip digital health feedback systems with reasonable security features.
- Digital Pills. Several forms of “digital pills” that send information from places like the digestive tract or bloodstream are being developed, with a few already in use. Digital pills, which combine ingestible microchip sensors with pharmaceuticals can, for instance, control and monitor the release of active pharmaceutical ingredients after digestion. They can also record whether, when and in what quantity a drug is released, as well as information about the physical state of the person taking the drug, such as temperature, activity level, heart rate and respiration.
- Confidentiality of Health Information. Existing state and federal laws protect the confidentiality of health information, but medical information (under California's CMIA) and protected health information (under the federal Health Insurance Portability and Accountability Act (HIPAA)) generally receive a classification, as protected, only because the information originates with a health care provider or other "covered entity," as defined in current law. Information generated by a digital health feedback system, however, would not necessarily be captured under the existing definitions.
- Prior Legislation. AB 2167 (Chau), of the 2017-18 Legislation Session, is substantially similar to this bill and died on the Senate Floor.
AB 2935 (Chau), of 2018, of the 2017-18 Legislation Session would have prohibited an operator of a commercial health monitoring program (CHMP) from intentionally sharing, selling or disclosing individually identifiable health monitoring information in its possession or derived from a CHMP without first obtaining the consumer’s consent. AB 2935 was referred to the Senate Judiciary Committee and never heard.
AB 375 (Chau), Chapter 55, Statutes of 2018, enacts the California Consumer Privacy Act of 2018, and grants a consumer a right to request a business to disclose the categories and specific pieces of personal information that it collects about the consumer, the categories of sources from which that information is collected, the business purposes for collecting or selling the information, and the categories of third parties with which the information is shared.
SB 1121 (Dodd), Chapter 735, Statutes of 2018, modifies the California Consumer Privacy Act of 2018, by requiring a business that collects personal information about a consumer to disclose the consumer’s right to delete personal information in a form that is reasonably accessible to consumers, as specified.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 23, 2019
ASSEMBLY COMMITTEE ON PRIVACY AND CONSUMER PROTECTION
Ed Chau, Chair
ABPCA Bill Id:AB 384 (
Author:Chau) – As Introduced Ver:February 5, 2019
SUBJECT: Information privacy: digital health feedback systems
SUMMARY: This bill would define “medical information” for purposes of the Confidentiality of Medical Information Act (CMIA) to include any individually identifiable information in the possession of or derived from a digital health feedback system, as specified. The bill would also require a manufacturer that sells or offers to sell a digital health feedback system to a consumer in California to equip the system with reasonable security features. Specifically, this bill would:
- Define “digital health feedback system” to mean an ingestible sensor that collects and sends information about an individual that may be used in conjunction with either of the following:
- A sensor or device placed inside or worn on the body that collects and sends information about an individual.
- A software platform that is connected to the internet, directly or indirectly, or to another device that receives and displays information collected or sent from a sensor or device as described in the paragraph above.
- Include within the definition of “medical information” in the CMIA “any individually identifiable information in electronic or physical form, in possession of or derived from, a digital health feedback system.”
- Require any manufacturer or operator that sells or offers to sell a digital health feedback system to a consumer in California to equip the device or software application, and the system, with reasonable security features appropriate to the nature of the device, software application, or system, and the information it may collect, contain, or transmit, and require the features to protect the system and any information contained therein from unauthorized access, destruction, use, modification, or disclosure.
EXISTING LAW:
- Specifies, under the federal Health Insurance Portability and Accountability Act (HIPAA), privacy protections for patients’ protected health information and generally provides that a covered entity, as defined (health plan, health care provider, and health care clearing house), may not use or disclose protected health information except as specified or as authorized by the patient in writing. (45 C.F.R. Sec. 164.500 et seq.)
- Provides, under the California Constitution, that all people have inalienable rights, including the right to pursue and obtain privacy. (Cal. Const. art. I, Sec. 1.)
- Prohibits, under CMIA, providers of health care, health care service plans, or contractors, as defined, from sharing medical information without the patient’s written authorization, subject to certain exceptions. (Civ. Code Sec. 56 et seq.)
- Defines “medical information” to mean any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment. CMIA defines “individually identifiable” to mean that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, or social security number, or other information that, alone or in combination with other publicly available information, reveals the individual’s identity. (Civ. Code Sec. 56.05(g).)
- Provides that any business organized for the purpose of maintaining medical information in order to make the information available to an individual or to a provider of health care at the request of the individual or the provider of health care, for purposes of allowing the individual to manage his or her information, or for the diagnosis of treatment of the individual, shall be deemed to be a provider of health care subject to the requirements of the CMIA. (Civ. Code Sec. 56.06(a).)
- Provides that any provider of health care, health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of written or electronic medical records shall be subject to damages in a civil action or an administrative fine, as specified. (Civ. Code Sec. 56.36.)
FISCAL EFFECT: Unknown
COMMENTS:
- Purpose of the bill: This bill seeks to implement reasonable regulations for the use of “digital pills” by defining “digital health feedback systems,” amending the definition of “medical information” in the CMIA, and requiring that manufacturers and operators equip digital health feedback systems with reasonable security features appropriate to protect the system and any information contained therein. This is an author-sponsored bill.
- Author’s statement: According to the author, “[w]hile technology stands to improve how healthcare is delivered, these advancements do not come without risk. Health and medical information is, by its very nature, deeply personal and sensitive. New technology makes medical information easily and quickly accessible via apps and websites, and California has ensured that medical information held by mobile devices is protected under our privacy laws. However, in order to be considered ‘medical information,’ this information generally needs to be generated by a healthcare provider. Information generated by a digital health feedback system, meaning at the patient level and outside of a medical facility, is not necessarily captured under the existing definition of medical information. However, information about whether a patient took their medication and how that medication interacted in their body is unquestionably of a medical nature. Therefore, it is imperative that the information generated by digital health feedback systems is classified as medical information, and developers and operators of hardware, software, and applications are prohibited from sharing this information and data without the patient’s informed consent.”
- Digital medicine: Technology enables individuals to receive more detailed and time-sensitive information about the world around them all the time. A network of devices with the ability to connect to the internet (commonly known as “the Internet of Things” or IOT) has created previously unimagined conveniences for consumers who have come to rely on connected devices such as cellphones, fitness applications, smart appliances, smart cars, and wearable devices.
The global digital health market has grown exponentially in the past five years, fueled by IoT development, increased mobile device adoption, and big data investment. (Chamberlin & Gretz, Internet of Things: Small IoT Projects Pay the Way for Future Transformation, BLUEMINE: HORRIZONWATCH (Mar. 6, 2016).) Historically, the medical device industry focused on implants and direct therapies, but new medical technologies also leverage connectivity and data aggregation, necessitating enhanced privacy protections to protect patients and/or consumers.
Research shows that a significant number of Americans depend on medical applications as part of their medical care, with the majority of smartphone users having downloaded a health application. (Krebs & Duncan, Health App Use Among US Mobile Phone Owners: A National Survey, 3 JMIR mHealth and UHealth 1, 5 (2015).) As of July 2018, Google Play had over 40,000 applications in the medical category and nearly 75,000 in the health and fitness category. These applications can collect an extraordinary amount of information, including a user’s sleep schedule, medication information, blood pressure, cholesterol level, menstrual cycle, blood oxygen level, and location.
Relevant to this bill, several forms of “digital pills” that send information from places like the digestive tract or bloodstream to an application have recently been developed, with a few already in use. These digital pills, which combine ingestible microchip sensors with pharmaceuticals and patches worn by the patient, can record whether, when, where and in what quantity a drug is released, as well as information about the physical state of the person taking the drug, such as temperature, activity level, heart rate, and respiration. Digital pills then transmit signals and information about the patient to devices like mobile phones, tablets, and computers belonging to the patient, the patient’s caregivers, or the patient’s doctor. (Avery & Liu, Bringing Smart Pills to Market: FDA Regulation of Ingestible Drug/Device Combination Products, 66 Food & Drug L.J. 329, 330-32 (2011).)
These pills and their accompanying technology stand to provide information that may drastically improve the lives of many people. For example, an estimated 50 % of patients with chronic diseases in developed countries do not take their medication, as prescribed. This can cause relapse and recurrence of chronic disease and results in an estimated $100 billion - $300 billion in avoidable healthcare costs. (Whitefield, Bus. Wire US FDA Accepts Digital Medicine Drug Application for Otsuka and Proteus Digital Health, (Sept. 10, 2015), found at < https://www.businesswire.com/news/home/20150910005497/en/ U.S.-FDA-Accepts-Digital-Medicine-Drug-Application > [as of Mar. 18, 2019].) By measuring medication adherence, digital health feedback systems could allow healthcare professionals to more effectively tailor treatment of chronic diseases to individual patients, which could both lead to better health outcomes and save billions of dollars in healthcare costs. (Id.)
Yet, despite digital health feedback systems’ potential for positive impact, there are significant concerns related to privacy and data security, which may act as barriers to their success. Specifically, should privacy laws proactively determine how information generated and collected by these systems is disclosed, and to whom? Furthermore, are current privacy and data collection laws sufficient to ensure that data created and transmitted via digital health feedback systems is secure? Consumer Reports, in support, argues that this bill is necessary because innovative medical technology was not contemplated when current laws were put in place. Consumer Reports writes in support:
In California, patient privacy is protected by the Confidentiality of Medical Information Act (CMIA)2 and the Health Insurance Portability and Accountability Act of 1996 (HIPAA)3. However, combined, these two laws only protect sensitive health information that is generated by healthcare providers, insurers and health plans, pharmaceutical companies, healthcare clearinghouses and businesses organized for the purpose of maintaining medical information. The information created by digital health feedback systems do not fall into this rubric. […]
AB 384 would protect sensitive information generated and collected by digital feedback
systems by expanding the definition of “medical information” under CMIA to include this new way of generating data. If enacted, this bill would align privacy rights around data collected by digital pills with all other medical information, and would also require that manufacturers apply appropriate data security standards to digital pills. These added protections would add certainty for patients that using smart pills will not jeopardize their privacy and potentially impact them in other areas of their lives. It is critical that AB 384 be put in place as the marketplace for this type of medical technology expands and becomes a prevalent feature of healthcare.
- State and federal medical privacy laws: HIPAA, enacted in 1996, guarantees privacy protection for individuals with regards to specific health information. (Pub.L. 104–191, 110 Stat. 1936.) Generally, protected health information (PHI) is any information held by a covered entity which concerns health status, provision of health care, or payment for health care that can be connected to an individual. HIPAA privacy regulations require health care providers and organizations to develop and follow procedures that ensure the confidentiality and security of PHI when it is transferred, received, handled, or shared. HIPAA further requires reasonable efforts when using, disclosing, or requesting PHI, to limit disclosure of that information to the minimum amount necessary to accomplish the intended purpose.
California’s CMIA also protects medical information and restricts its disclosure by health care providers, and health care service plans, as specified. Under existing law, a corporation organized for the purpose of maintaining medical information in order to make that information available to the patient, or a provider at the request of the patient for purposes of diagnosis or treatment, is deemed to be a provider of health care subject to the requirements of the CMIA. AB 658 (Calderon, Ch. 296, Stats. 2013) further ensured that any business that offers software or hardware to consumers, including a mobile application or other related device, that is designed to maintain medical information or for the diagnosis, treatment, or management of a medical condition of the individual, is also subject to the CMIA. While the chaptered version of AB 658 had no recorded opposition, the Chamber of Commerce opposed an earlier version of that bill because it was “unclear which mobile application software providers [would] be included. There are many small companies offering a variety of mobile apps that may be captured in the bill. For instance, it is difficult to determine if an app used for health fitness would be captured.” To address those concerns, the author of AB 658 accepted amendments in the Assembly Judiciary Committee which clarified that the provisions of the bill would apply only to medical information, as defined by the CMIA, meaning information which originates with a covered entity.
Subsequently, the Legislature considered AB 2688 (Gordon, 2016) which sought to regulate the disclosure of information in possession of or derived from a commercial health monitoring program to a third party without providing clear and conspicuous notice and obtaining the consumer’s affirmative consent. The introduced version of that bill would have expanded the CMIA to cover commercial health information devices (such as the “FitBit”), but was amended on March 28, 2016 to separate its provisions from CMIA and shift those requirements to a separate chapter in the Business and Professions Code. When AB 2688 ultimately died on the Senate floor, privacy advocates were in opposition because the bill did not create strong enough protections for privacy, whereas a coalition of technology companies were also in opposition because the bill in its current form would result in “unintended consequences, logistical difficulties, and consumer harm.”
As with the bills noted above, the Legislature must once again consider the question of whether health and medical information are adequately protected by existing privacy laws. Despite the sensitive nature of information collected by mobile medical and health applications, and now by digital pills, medical information and PHI generally only receive such a classification when it originates with a health care provider or other covered entity. As noted in a recent law review article, despite HIPAA and CMIA protecting health information in the hands of health care professionals and health care institutions, these laws do not apply to user-generated data from medical apps, nor do they apply to information that is not traditionally considered health information (such as geolocation or gait) that could be used to discriminate against a person because of an association with a medical condition. (Andrews, A New Privacy Paradigm in the Age of Apps (2018) 53 Wake Forest L. Rev. 422 (hereinafter, Andrews).)
Additionally, despite California law seemingly protected by applications designed for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition, the law only protects medical information (meaning it must be generated in a traditional healthcare setting), and the statute explicitly states that other protections of confidentiality in the physician-patient relationship do not apply. (See Civ. Code Sec. 56.06(b) and (c).)
Accordingly, this bill would proactively designate information generated by digital health feedback systems as medical information, thus determining, at least for the purposes of California’s CMIA, that the manufacturers, operators, and developers of the digital pill software and hardware that collect and send health data cannot sell or disclose an individual’s information without prior authorization. Notably, last year, the Legislature enacted the CCPA (AB 375, Chau, Ch. 55, Stats. 2018), which gives consumers certain rights regarding their PI, including: (1) the right to know what PI that is collected and sold about them; (2) the right to request the categories and specific pieces of PI the business collects about them; and (3) the right to opt out of the sale of their PI, or opt-in in the case of minors under16 years of age. Largely due to the necessary information sharing in the healthcare setting and the protections found in CMIA and HIPAA, medical information and protected health information, as defined in those bodies of law, are exempt from the CCPA. Similarly, providers of health care under CMIA and covered entities under HIPAA are exempt from the CCPA. Staff notes that due to the nature of the information generated by digital health feedback systems, and the fact that they are used in conjunction with a prescription while the patient is under the care of a doctor, CMIA is likely a better governing scheme than the CCPA for this information, in that CMIA allows information sharing amongst healthcare providers, thereby facilitating better healthcare.
- Last year’s digital pill legislation: Last year this Committee passed AB 2167 (Chau, 2018), which was substantially similar to this bill. AB 2167 received opposition in the Senate from the Advanced Medical Technology Association (AdvaMed) and the California Life Sciences Association who argued that it would have prematurely regulated digital health feedback systems and impose significant compliance and legal costs. Specifically, the opposition argued:
The additional liability under the California Medical Information Act is unnecessary and overly burdensome given the substantial bodies of applicable regulations and guidance, both federal and private, at the national level (international standards are also important), all of which have been closely followed by innovators in this space. It is important to note that use of this technology requires willing and knowing participation from the patient – the technology will not work unless used correctly and the patient maintains ownership and control of any data that is generated.
This year, the same two groups are in opposition, but argue that they are already subject to CMIA’s confidentiality and non-disclosure provisions. “The additional liability under the California Medical Information Act (CMIA) is unnecessary and overly burdensome for two key threshold reasons. First, the CMIA already covers the core activities ostensibly targeted by AB 384. Currently, the CMIA deems any business that offers software or hardware to consumers, including a mobile application or other related device designed to maintain medical information, for purposes of allowing the individual to manage his information, or for the diagnosis, treatment, or management of a medical condition of the individual, to be a ‘provider of health care’ (Civil Code [sec.] 56.06(b)). This means such businesses, including those involved in digital health feedback systems, are already subject to the CMIA’s confidentiality and nondisclosure requirements with respect to any individually identifiable patient medical information they access or maintain.”
As noted above in Comment 4, CMIA does not necessary apply to medical or health information generated at the individual level, outside of a traditional healthcare setting. In fact, a strict reading of the relevant statute would allow an application developer or business that maintains the application data, to avoid liability under CMIA by simply claiming that they are providing information for entertainment purposes, rather than for medical or health purposes. It is also questionable, under this reasoning, whether information that may predict health status (such as gait information), that an individual is not using to assess their own health, but could be used by others to assess patient health, would be protected under the CMIA. (See Civ. Code Sec. 56.06(b).)
The opposition further notes that “the FTC through its Section 5 ‘unfair and deceptive business practices’ enforcement authority has broad, sweeping powers to regulate in this area where business practices diverge from statements or claims made to the patient. As manufacturers already grant total control and ownership to the patient, if data were used in any other way, the manufacturer would be in violation of the Federal Trade Commission Act. The [Food and Drug Administration] FDA and FTC have for years maintained a memorandum of understanding (MOU) to facilitate enforcement over medical technology. Additionally, last year, the FDA announced an expansion of regulation into the digital health space – we hope to see how this regulatory framework functions before imposing additional regulation at the state level that could conflict with or impose needless burdens on a new technology that has not shown deficiencies with respect to data stewardship.”
Staff notes that while the power to address unfair or deceptive trade practices is indeed broad, the FTC has generally only chosen to take action when an application developer fails to disclose in advance that it will be invading a person’s privacy. In other words, if an application developer states in advance that it will be collecting and sharing a person’s information, the FTC will generally not argue that the developer misrepresented its practices. (See, e.g., PayPal Settles FTC Charges that Venmo Failed to Disclose Information to Consumers About the Ability to Transfer Funds and Privacy Settings; Violated Gramm-Leach-Bliley Act, FTC (Feb. 27, 2018).)
On this point, research shows that these privacy related-issues extend beyond digital health feedback systems and are endemic to digital medicine itself. “People care deeply about the privacy of the information collected by their medical apps. Yet our studies show that information from medical apps is collected directly and indirectly and then shared with marketers and other third parties in ways which can harm the app user. Vast in scope and packaged with information not traditionally thought of as implicating health, information from medical apps is sold to third parties including employers and insurers. In one instance, an insurer bought health-related digital data from about three million people from a data aggregator. […] Existing laws do not sufficiently protect the privacy of medical app users. An alternative approach is necessary that recognizes the unique challenges raised by medical apps in terms of the scope of information they collect, the nature of that information, and the context in which it is collected.” (Andrews at p. 28.)
This bill, which would extend the existing CMIA framework of consent prior to disclosure of personal information to the data collected by digital health feedback systems, would hold digital health feedback system creators and operators to the same high standards as healthcare providers, while still allowing for the necessary sharing of information for patient health care. Staff notes that the author and the opposition have been working together in an effort to find common ground on these issues, and have discussed expanding the provisions of the bill to apply to digital medicine more broadly to ensure that the privacy of California residents is appropriately protected, while still ensuring that they can benefit from the advancements of digital medicine.
- Manufacturers that sell digital health feedback systems must equip systems with reasonable security features: The health care industry is plagued with data breaches. (Snell, How Much Do Healthcare Data Breaches Cost Organizations? Health IT Security, (Feb. 2018) <https://healthitsecurity.com/news/how-much-do-healthcare-data-breaches-cost-organizations> [as of Mar. 18, 2019].) Each act of data transmission presents some risk that data will be breached, even with security precautions in place, and the frequency of breaches is increasing. In 2015, 113 million electronic health records were breached. (See Ponemon Inst., Sixth Annual Benchmark Study on Privacy & Security of Healthcare Data (2016) (discussing “the increased frequency of [data] breaches” in the health care industry). At the same time, connected medical devices – components of the so-called IoT – are multiplying, opening more holes in security.
Digital health feedback systems stand to greatly improve adherence to prescriptions, and thus healthcare, as discussed in Comment 3, above. However, at the core of the system are digital applications and software, which are ripe for data security breach. Accordingly, this bill would require a manufacturer or operator that sells or offers to sell a digital health feedback system to a consumer in California equip the device or software application, and the system, with reasonable security features appropriate to the nature of the device, software application, or system, and the information it may collect, contain, or transmit, and require the features to protect the system and any information contained therein from unauthorized access, destruction, use, modification, or disclosure.
AdvaMed and the California Life Sciences Association additionally argue in opposition that requiring “reasonable security features” would create persistent questions of liability for the industry.
[A] thoroughly comprehensive regulatory and policy frameworks exist at both the national and international levels, and these frameworks are continuing to evolve in important ways. These substantial bodies of applicable regulations, guidance, and standards, both federal and private at consequences for doing so would be significant (e.g., a barrier to entry for certain markets and costly redesigns of technology, among many other things). It is important to note that use of this technology requires willing and knowing participation from the patient – the technology will not work unless used correctly and the patient maintains ownership and control of any data that is generated.
Staff notes that this requirement is consistent with other proposals that the Legislature has reviewed in the past few years. (See, e.g., AB 658 (Calderon, Ch. 296, Stats. 2013) and AB 1298 (Snyder, Ch. 699, Stats. 2007).) This language was crafted last year after some groups connected with the pharmaceutical industry expressed concern that the digital sensor component of the digital health feedback system which they are responsible for, cannot be “equipped” with reasonable security features as required by this bill. Indeed, the only sensor approved currently by the FDA is “a silicon chip about the size of a sand particle. With no battery or sensor, it is powered by the body itself. The chip contains small amounts of copper and magnesium. After being ingested the chip will interact with digestive juices to produce a voltage that can be read from the surface of the skin through a detector patch, which then sends a signal via mobile phone to inform the doctor that the pill has been taken.” (Murray, No More Skipping Your Medicine—FDA Approves First Digital Pill, Forbes (Aug. 9, 2012).)
In response to the concerns raised by the opposition, the author writes:
It is important to remember that while technology stands to improve how healthcare is delivered, these advancements do not come without risk. Information that is generated by a digital health feedback system, meaning at the patient level and outside of a medical facility, will not necessarily be captured under the existing definition of medical information. But information about whether a patient took his or her medication and how that medication interacted in his or her body is unquestionably of a medical nature. Therefore it is imperative that the information generated by digital health feedback systems is classified as medical information, and developers and operators of hardware, software, and applications are prohibited from sharing this information and data without the patient’s informed consent.
Further, California cannot control federal regulations. As a Legislature, we often go beyond what the federal government requires or is willing to offer to individuals whose rights have been violated. The world of medical technology should be no different. That the opposition claims this field is regulated by federal “guidance” should not stop California from protecting the privacy of its residents. It is entirely within our purview to codify best practices in an industry to ensure all actors in a field are acting with due care.
- Prior legislation: AB 2167 (Chau, 2018) was substantially similar to this bill. AB 2167 died on the Senate floor.
AB 375 (Chau, Ch. 55, Stats. 2018) See Comment 4.
AB 2935 (Chau, 2018) would prohibit the operator of a commercial health monitoring program from intentionally sharing or disclosing a consumers individually identifiable health monitoring information to or with a third party without first obtaining the consumers consent.
AB 2688 (Gordon, 2016) See Comment 4.
AB 2747 (Assembly Committee on Judiciary, Ch. 913, Stats. 2014) extends CMIA provisions to any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information in order to make the information available to an individual or a provider of health care at the request of the individual or a provider of health care.
AB 658 (Calderon, Ch. 296, Stats. 2013) see Comment 4.
AB 1298 (Snyder, Ch. 699, Stats. 2007) subjects any business organized to maintain medical information for purposes of making that information available to an individual or to a health care provider, as specified, to the provisions of CMIA.
- Double-referral: This bill was double-referred to the Assembly Committee on Health, where it was heard on March 26, 2019, and passed on a 10 - 3 vote.
REGISTERED SUPPORT / OPPOSITION:
Support
Consumer Reports
Opposition
Advanced Medical Technology Association
California Life Sciences Association
Analysis Prepared by: Nichole Rapier / P. & C.P. / (916) 319-2200
Date of Hearing: March 26, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 384
Author:(Chau) – As Introduced Ver:February 5, 2019
SUBJECT: Information privacy: digital health feedback systems.
SUMMARY: Revises the Confidentiality of Medical Information Act (CMIA), to expand the definition of medical information to include any individually identifiable information in electronic or physical form in possession of, or derived from, a digital health feedback system, as defined. Requires a manufacturer that sells or offers to sell a device or software application that may be used with a digital health feedback system to a consumer in California to equip the device or software application, and system with reasonable security features appropriate to the nature of the device, system application, and system, and the information it may collect, contain, or transmit; and, to protect the system and any information from unauthorized access, destruction, use, modification, or disclosure. Specifically, this bill:
- Defines digital health feedback system as an ingestible sensor that collects or sends information about an individual and used in conjunction with either, or both, of the following:
- A sensor or device placed inside or worn on the body that collects or sends information about an individual; and,
- A software platform that is connected to the Internet, directly or indirectly, or to another device that receives and displays information collected or sent from a sensor or device in 1) a) above.
- Expands the definition of medical information to also include any individually identifiable information in electronic or physical form in possession of, or derived from, a digital health feedback system.
- Defines unauthorized access, destruction, use, modification, or disclosure as access, destruction, use, modification, or disclosure that is not authorized by the person about whom the information pertains unless authorized or required by law.
- Requires a manufacturer that sells or offers to sell a device or software application that may be used with a digital health feedback system to a consumer in California to equip the device or software application, and system with reasonable security features appropriate to the nature of the device, system application, and system, and the information it may collect, contain, or transmit; and, to protect the system and any information from unauthorized access, destruction, use, modification, or disclosure.
- Makes other technical and conforming changes.
EXISTING LAW:
- Establishes under federal law, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) which sets standards for privacy of individually identifiable health information and security standards for the protection of electronic protected health information, including, through regulations, that a HIPAA covered entity may not condition the provision of treatment, payment, enrollment in the health plan, or eligibility for benefits on the provision of an authorization, except under specified circumstances. Provides that if HIPAA’s provisions conflict with state law, the provision that is most protective of patient privacy prevails.
- Prohibits, under the state CMIA, a provider of health care, a health care service plan, a contractor, a corporation and its subsidiaries and affiliates, or any business that offers software or hardware to consumers, including a mobile application or other related device, as defined, from intentionally sharing, selling, using for marketing, or otherwise using any medical information, as defined, for any purpose not necessary to provide health care services to a patient, except as expressly authorized by the patient, enrollee, or subscriber, as specified, or as otherwise required or authorized by law. States that a violation of these provisions that results in economic loss or personal injury to a patient is a crime.
- Defines, for purposes of the CMIA, medical information to mean any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment. Defines individually identifiable to mean that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, social security number, or other information that, alone or in combination with other publicly available information, reveals the individual’s identity.
- Provides that if HIPAA’s provisions conflict with a provision of state law, the provision that is the most protective of patient privacy prevails.
- Prohibits providers of health care, health care service plans, or contractors, as defined, from sharing medical information without the patient’s written authorization, subject to certain exceptions.
- Deems any business organized for the purpose of maintaining medical information in order to make the information available to an individual or to a provider of health care at the request of the individual or the provider of health care, for purposes of allowing the individual to manage their information, or for the diagnosis and treatment of the individual, to be a provider of health care subject to the requirements of the CMIA.
- Deems any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information in order to make the information available to an individual or a provider of health care at the request of the individual or a provider of health care, for purposes of allowing the individual to manage their information, or for the diagnosis, treatment, or management of a medical condition of the individual, to be deemed to be a provider of health care subject to the requirements of the CMIA.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, while technology stands to improve how healthcare is delivered, these advancements do not come without risk. Health and medical information is, by its very nature, deeply personal and sensitive. New technology makes medical information easily and quickly accessible via smartphone applications (apps) and Websites, and California has ensured that medical information held by mobile devices is protected under our privacy laws. However, in order to be considered “medical information,” this information generally needs to be generated by a healthcare provider. Information that is generated by a digital health feedback system, meaning at the patient level and outside of a medical facility, will not necessarily be captured under the existing definition of medical information. But information about whether a patient took his or her medication and how that medication interacted in his or her body is unquestionably of a medical nature, according to the author. Therefore, it is imperative that the information generated by digital health feedback systems is classified as medical information, and developers and operators of hardware, software, and applications are prohibited from sharing this information and data without the patient’s informed consent.
- BACKGROUND. In November 2017, the U.S. Food and Drug Administration (FDA) approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal. It is important to note that Abilify MyCite’s prescribing information (labeling) notes that the ability of the product to improve patient compliance with their treatment regimen has not been shown.
- A 2017 New York Times article described that for the first time, the FDA has approved a digital pill, specifically, a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine. This approval marks a significant advance in the growing field of digital devices designed to monitor medicine-taking and to address the issue of patients not taking drugs as prescribed. The article notes that experts estimate that so-called nonadherence or noncompliance to medication costs about $100 billion a year because patients get sicker and need additional treatment or hospitalization. Patients who agree to take the digital medication can sign consent forms allowing their doctors and up to four other people, including family members, to receive electronic data showing the date and time pills are ingested. A smartphone app will allow patients to block recipients anytime they change their mind. Although voluntary, the technology is still likely to prompt questions about privacy and whether patients might feel pressured to take medication in a form their doctors can monitor. The article also notes that companies are developing digital medication technologies, including another ingestible sensor and visual recognition technology capable of confirming whether a patient has placed a pill on the tongue and has swallowed it and not all will need regulatory clearance, and some are already being used or tested in patients with heart problems, stroke, HIV, diabetes and other conditions.
- A 2016 Vanderbilt Journal of Entertainment and Technology Law article, titled “Just What the Doctor Ordered: Protecting Privacy Without Impeding Development of Digital Pills,” analyzed digital pills in the context of the privacy and data security implications that could put consumers at risk. Digital pills that send information from places like the human digestive tract or bloodstream are being developed, with a few already in use. These pills could stand to provide information that could drastically improve the lives of many people, but they also have privacy and data security implications that could put consumers at great risk. The article notes that ingestible sensors have great potential to provide financial and health related benefits. The risks of the digital pill with regard to privacy and data security, however, may lead some to call for preemptive regulation. The article contends that rather than immediately limiting information use, policymakers should focus on improving the methods by which consumers can be educated and give consent. The article also states that it is not clear which privacy laws will actually apply to digital pills as HIPAA applies only to individually identifiable health information that is stored or transmitted by "covered entities" and their "business associates." Covered entities are usually health care providers, health insurers, or health care clearinghouses that process billing information, not pharmaceutical companies. Pharmaceutical companies can be considered "business associates" if they perform "functions or activities on behalf of, or certain services for, a covered entity that involve the use or disclosure of protected health information.
- RELATED LEGISLATION.
- AB 648 (Nazarian) of 2019 prohibits health care service plans and insurers from offering an incentive or reward to an enrollee or member, or insured (“individual”), based on adherence to a wellness program, and would prohibit health care service plans or insurers from taking any adverse action, as defined, if the action of the health care service plans or insurers is in response to a matter related to a wellness program, such as an individual’s election to not participate in a wellness program. AB 648 is pending in Assembly Health Committee.
- SB 561 (Jackson) of 2019 expands a consumer’s rights to bring a civil action for damages to apply to other violations under the California Consumer Privacy Act of 2018. SB 561 is pending in Senate Judiciary Committee.
- PREVIOUS LEGISLATION.
- AB 2167 (Chau) of 2018 is substantially similar to this bill and died on the Senate Floor.
- AB 2935 (Chau) of 2018 would have prohibited an operator of a commercial health monitoring program (CHMP) from intentionally sharing, selling, or disclosing individually identifiable health monitoring information in its possession or derived from a CHMP without first obtaining the consumer’s consent. AB 2935 was never heard in Senate Judiciary Committee.
- AB 375 (Chau), Chapter 55, Statutes of 2018, enacts the California Consumer Privacy Act of 2018, and grants a consumer a right to request a business to disclose the categories and specific pieces of personal information that it collects about the consumer, the categories of sources from which that information is collected, the business purposes for collecting or selling the information, and the categories of third parties with which the information is shared.
- SB 1121 (Dodd), Chapter 735, Statutes of 2018, modifies the California Consumer Privacy Act of 2018, by requiring a business that collects personal information about a consumer to disclose the consumer’s right to delete personal information in a form that is reasonably accessible to consumers, as specified.
- AB 2688 (Gordon) of 2016 would have prohibited an operator of a CHMP from intentionally sharing, selling, or disclosing individually identifiable health monitoring information in possession of or derived from a commercial health monitoring program to a third party, as defined, without first
providing clear and conspicuous notice and obtaining the consumer’s affirmative consent, as provided, and would have provided that individually identifiable information may be disclosed to specified entities without consent under specified circumstances, including to a government official if necessary to prevent an emergency involving the danger of death or serious physical injury to a person, if the disclosing entity provides notice of the disclosure as soon as practicable. AB 2688 would have also required an employer that receives health monitoring information in possession of or derived from a commercial health monitoring program to establish procedures to preserve the confidentiality and security of that information, as provided. AB 2688 died on the Senate third reading file. - SB 138 (Ed Hernandez), Chapter 444, Statutes of 2014, specifies the manner in which a health care service plan or health insurer is required to maintain confidentiality of medical information regarding the treatment of an insured, subscriber, or enrollee.
- AB 658 (Calderon), Chapter 296, Statutes of 2013, applies the prohibitions of the CMIA to any business that offers software or hardware to consumers, including a mobile application or other related device that is designed to maintain medical information to allow an individual to manage his or her information, or for the diagnosis, treatment, or management of a medical condition of the individual.
- AB 1298 (Jones), Chapter 699, Statutes of 2007, applies the prohibitions of the CMIA to any business organized for the purpose of maintaining medical information to allow an individual to manage his or her information, or for the treatment or diagnosis of the individual.
- OPPOSITION. Advanced Medical Technology Association and the California Life Sciences Association (AdvaMed and CLSA) are opposed to this bill because it would impose a new and undefined “reasonable security features” standard on a constantly evolving and innovating field, creating persistent questions of liability for the industry and/or a constant game of catch-up by California regulators. AdvaMed and CLSA also contend that thoroughly comprehensive regulatory and policy frameworks exist at both the national and international levels which are continuing to evolve.
- DOUBLE REFERRAL. This bill has been double-referred; upon passage of this committee, it will be referred to the Assembly Privacy and Consumer Protection Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
None on file.
Opposition
Advanced Medical Technology Association
California Life Sciences Association
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):